论文部分内容阅读
目的:观察诺合龙对高海拔地区糖耐量减低(IGT)的干预治疗作用。方法:在海拔高于2 000m生活的高危人群健康体检中空腹血糖(FPG)(5.6~7.0)mmol/L及住院和就诊患者中以口服75g葡萄糖耐量试验进行筛查。按1999年WHO符合IGT诊断标准的患者共30例随机分成两组,治疗组予以胰岛素促泌剂诺合龙1mg每天1次;对照组不予以诺合龙及任何降糖药,观察期为1年。两组患者均进行糖尿病教育,强调控制饮食及运动的重要性。结果:治疗组糖尿病的发生率为6.7%;对照组糖尿病发生率为28.6%,两组比较差异有统计学意义(P<0.05)。结论:诺合龙对IGT干预治疗可明显降低糖尿病的发生率。
Objective: To observe the effects of Nongkailong on the intervention therapy of impaired glucose tolerance (IGT) in high altitude areas. Methods: Screening was performed in 75 g glucose tolerance test of fasting blood glucose (FPG) (5.6-7.0 mmol / L) and hospitalization and treatment of high-risk population above 2 000 m altitude. According to the 1999 WHO criteria for IGT diagnosis of 30 patients were randomly divided into two groups, the treatment group was given insulin secretagogues 1mg normoconazole 1 day; the control group did not receive nortron and any hypoglycemic agents, the observation period of 1 year. Diabetes education was conducted in both groups, emphasizing the importance of diet and exercise control. Results: The incidence of diabetes in the treatment group was 6.7%. The incidence of diabetes in the control group was 28.6%. There was significant difference between the two groups (P <0.05). Conclusion: Nong Long on IGT intervention can significantly reduce the incidence of diabetes.